For research use only. Not for use in humans.

Onartuzumab (Anti-HGFR / c-Met)

Synonyms: MetMAb Cat.No.A2468 Purity:99%

Onartuzumab (Anti-HGFR / c-Met) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. MW: 99.51 KD.

Click to purchase the isotype control of Onartuzumab (Anti-HGFR / c-Met)

Quality Control

Batch: A246801 Purity: 99% Protein concentration: 5.76mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Specificity

Name	Citation	c-Met	Others
Foretinib	94	++++	KDR,Tie-2,VEGFR3/FLT4
PHA-665752	96	++	RON,Flk1
SU11274	67	++
SGX-523	136	+++
BMS-777607	63	+++	Axl,RON,Tyro3
Tivantinib	49	+
JNJ-38877605	54	+++
PF-04217903	22	++
MGCD-265 analog	12	++++	RON,VEGFR1,VEGFR2
BMS-754807	54	++	Insulin Receptor,IGF-1R,TrkB
BMS-794833	2	+++	VEGFR2
AMG-208	0	++
MK-2461	4	++++	c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100)
Golvatinib (E7050)	8	+	VEGFR2
AMG-458	0	++++
Tepotinib	23	+++
NVP-BVU972	1	+
XL092	0	+	VEGFR2,AXL,MER
UNC2025	7	+	FLT3,Mer,Axl
Ningetinib	0	++	Axl,VEGFR2
Elzovantinib (TPX-0022)	0	++++	SRC,CSF1R
AMG-1	0	+++	RON
Pamufetinib (TAS-115)	0	+	recombinant VEGFR2
JNJ-38877618(OMO-1)	0	+++	MET (M1268T)
Altiratinib	3	+++	MET Y1230C,TrkA,TrkC
SAR125844	0	++++	MET Y1235D,MET M1250T,TRKA/NTRK1
Glumetinib	1	++++
Savolitinib (AZD6094)	19	++	p-Met
CEP-40783 (RXDX-106)	7	+	Axl,Tyro3,MER
S49076	1	++++	Mer,Axl,FGFR3
Merestinib (LY2801653)	11	+++	DDR1,AXL,FLT3
AMG 337	2	++++
NPS-1034	3	+	Axl
Amuvatinib (MP-470)	21	✔	c-RET,RAD51,c-Kit (D816H)
Glesatinib	1	✔	SMO
Terevalefim	1	✔
Licochalcone D	0	✔	Caspase,EGFR,JAK2
BAY-474	0	✔
Bozitinib	1	✔
Pulsatilla saponin D	1	✔
Sodium L-ascorbyl-2-phosphate	3	✔
Norcantharidin	3	✔	EGFR

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Onartuzumab (Anti-HGFR / c-Met) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. MW: 99.51 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1133766-06-9
Molecular Weight	99.51 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.